Selective, competitive CYP2C9 inhibitor (Ki = 0.3 µM). Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Inhibits bradykinin-induced tPA release.
Shipped In
Normal
Grade
Moligand™
Action Type
INHIBITOR
Mechanism of action
Bacterial dihydropteroate synthase inhibitor
Note
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Properties
ALogP
1.5
Associated Targets
CTNNBIP1Tbio Beta-catenin-interacting protein 1 0 Activities
1.Bourrié M, Meunier V, Berger Y, Fabre G. (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.. J Pharmacol Exp Ther, 277 (1):(321-32). [PMID:8613937]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
K2217226